Investors

2023

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.

Fipros (www.fipros.dk) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome® under licence.

This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome®  in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Fipros to manufacture SlimBiome® within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2022

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.

Fipros (www.fipros.dk) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome® under licence.

This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome®  in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Fipros to manufacture SlimBiome® within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2021

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.

Fipros (www.fipros.dk) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome® under licence.

This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome®  in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Fipros to manufacture SlimBiome® within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2020

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.

Fipros (www.fipros.dk) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome® under licence.

This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome®  in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Fipros to manufacture SlimBiome® within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2019

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.

Fipros (www.fipros.dk) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome® under licence.

This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome®  in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Fipros to manufacture SlimBiome® within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2018

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.

Fipros (www.fipros.dk) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome® under licence.

This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome®  in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to work with Fipros to manufacture SlimBiome® within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.